knowledge -WSS

knowledge

author：entertainment 2025-10-01 12:54:51 - browse：83914

A man enters the Regeneron Clinic at a monoclonal antibody treatment site in Pembroke Pines, Florida – politics and policy coverage from STAT — Regeneron agreed to price limits for a new Covid-19 drug that will be developed in partnership with the Department of Health and Human Services. CHANDAN KHANNA/AFP via Getty Images

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.

The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

The deal was part of the White House’s Project NextGen initiative, which includes $5 billion in new vaccines and therapies. HHS announced that it is spending $326 million to help Regeneron develop a new monoclonal antibody to prevent Covid-19. Regeneron in January announced plans to start testing a potentially variant-proof antibody, which is set to go into clinical trials later this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Readout LOUD podcast: Live from STAT Breakthrough Summit West

focus

WSS

NVIDIA and Google execs on the future of AI and drug discovery

When prostate cancer spreads, where it goes matters

Everything to know for the next Powerball drawing as jackpot hits $1 billion

When prostate cancer spreads, where it goes matters

NVIDIA and Google execs on the future of AI and drug discovery

With measles on the rise, a personal story of a devastating disease

leisure time

knowledge

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

With measles on the rise, a personal story of a devastating disease

Duchenne breakthrough therapy leaves behind pioneering families

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Anesthesiologist group: stop taking Ozempic before surgery

Venture capitalist Bob Kocher on the state of digital health

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

J&J expands global access to TB drug amid advocacy campaign

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

NVIDIA and Google execs on the future of AI and drug discovery

hotspot

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

Wearables generate powerful data but its not useful to doctors, yet

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

Who gets to use the title 'doctor'?

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

explore

focus

hotspot

hotspot